Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating
Guggenheim Adjusts Price Target on Regeneron Pharmaceuticals to $1,180 From $1,040, Maintains Buy Rating
古根海姆將再生元製藥公司的目標價格從1,040美元上調至1,180美元，維持買入評級。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊